

EFFECTIVE OCTOBER 1, 2023

Permanent J-code for SYFOVRE: J2781

Billing and Coding Guide

Phone: 888-APELLIS (888-273-5547) 8 AM-8 PM ET, Monday-Friday

Portal: ApellisAssistGA.com

Apellis

Fax: 888-405-6966

Website: SyfovreECP.com

and should not be construed as legal advice.

The coding information in this document is provided for informational purposes only, is subject to change,

This guide is intended to provide general information for submitting claims to payers for reimbursement. In no way should this information be considered a guarantee of coverage or reimbursement for any product or service. Coding and coverage policies change periodically, often without warning. The responsibility to determine coverage and reimbursement parameters and appropriate coding for a particular patient or procedure is always the responsibility of the provider. The codes listed herein may not apply to all patients or to all payers. Providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient. Practices should contact the applicable payer for more information on a payer's coverage, coding, and reimbursement policies.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION


CONTRAINDICATIONS

• SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

Please see additional Important Safety Information throughout and full Prescribing Information.

Coding Information

The following codes may be appropriate when billing for SYFOVRE and its related services.



The ICD-10-CM codes below are designated for GA¹

Geographic Atrophy ICD-10-CM Codes ¹ Used for diagnosis coding							
	Nonexudative age-related macular degeneration (AMD)	Right eye	Left eye	Bilateral			
	Advanced atrophic without subfoveal involvement	H35.3113	H35.3123	H35.3133			
GA	Advanced atrophic with subfoveal involvement	H35.3114	H35.3124	H35.3134			

	Administration CPT Code ^{2a} rt medical procedures and services
CPT code	Description
67028	Intravitreal injection of a pharmacologic agent, separate procedure

This may not be reflective of all CPT codes that may be used for SYFOVRE.

Modifiers Used in conjunction with the CPT Code at left to provide further information about the procedure or service

Modifier	Description
-LT	Lefteye
-RT	Right eye
-50	Bilateral

This is not an exhaustive list of modifiers, and requirements may vary by payer.

CPT=Current Procedural Terminology; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification. ^aCPT codes, descriptions, and material are ©2023 American Medical Association. All rights reserved.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Endophthalmitis and Retinal Detachments
 - o Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.





Please see additional Important Safety Information throughout and full Prescribing Information.

Coding Information (cont'd)

The following codes may be appropriate when billing for SYFOVRE and its related services.

ng Informat g codes may be appropriate ed services.	ion (cont'd) when billing for SYFOVRE		
HCPCS Code ³ U	sed for drugs administered by a me	edical professional	
Permanent J-code	CMS long descriptor ^a	Site of care	
J2781 effective October 1, 2023	Injection, pegcetacoplan, intravitreal, 1 mg	Physician office and hospital outpatient	

J2781 is a permanent, product-specific code assigned by CMS. Bill 15 units for each SYFOVRE injection. ^aDose descriptor is assigned by CMS; please see full prescribing information for approved dosing. The JZ modifier is required starting July 1, 2023.⁴ Please check with your patient's health plan for specific requirements.

National Drug Code (NDC) ^{5,6} Used	by the FDA as an identifier for drugs
10 - digit NDC for SYFOVRE Many NDCs listed on drug packaging are in a 10-digit format	11 – digit NDC for SYFOVRE The 11-digit NDC is derived from the 10-digit code. Many payers require the use of the 11-digit code
73606-020-01	73606-0020-01
Dosage form :	and strength
Intravitreal injection: 15 mg (0. clear, colorless to light yellow aque	

Revenue Codes ⁷ For hospital outpatient use only				
Revenue code	Description			
0636	Drugs requiring detailed coding			
0510	Clinic visit, general			

This is not an exhaustive list of revenue codes, and requirements may vary by payer.

CMS=Centers for Medicare and Medicaid Services; HCPCS=Healthcare Common Procedure Coding System.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (CONTINUED)

Neovascular AMD

o In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.





Sample CMS-1500 Claim Form: Physician Office

Below is a sample CMS-1500 form for SYFOVRE claim submissions.

The sample claim form provided below is for illustrative purposes only. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, payment policies, and fee schedules.

PICA	NATIONAL UNIFO	ORM CLAIM COMM	TTEE (NUCC) 02/12						PICA
1. MEDICAF		TRICARE	CHAMP	- HEALTH P	AN FECA	OTHER	1a. INSURED'S I.D. NUM	18ER	(For Program in Item
(Medicare		(ID#/DoD#) First Name, Middle	(Member	(D#) (D#)	(ID#)	(10#) EX	4. INSURED'S NAME (Li	et Nama, Eiret Nama, A	fidelo hifal)
ET ANERT O	arana (cast rearro,	not reality, mode		3. PATIENT'S BIR	M_	F	4. INSOMED STRAME (L	istivane, riistivane, n	illude initial)
5. PATIENT'S	ADDRESS (No., St	eet)		6. PATIENT RELA		RED Other	7. INSURED'S ADDRES	3 (No., Street)	
CITY			STATE				CITY		STATE
ZIP CODE		TELEPHONE (Indu	ute dance (Carda)	_					
21PCODE		()	ide Area Code)				ZIP CODE	((Include Area Code)
9. OTHER INS	URED'S NAME (La	st Name, First Name	a, Middle Initial)	10. IS PATIENT'S	CONDITION RELATI	ED TO:	11. INSURED'S POLICY	GROUP OR FECA NUN	/BER
a. OTHER INS	JRED'S POLICY O	R GROUP NUMBER	3	a. EMPLOYMENT	Ourrent or Previou	s)	a. INSURED'S DATE OF	BIRTH	SEX
					ES NO		MM DD		F
b. RESERVED	FOR NUCC USE			b. AUTO ACCIDEN	IT? PL (ES NO	ACE (State)	b. OTHER CLAIM ID (De	isignated by NUCC)	
C. RESERVED	FOR NUCC USE			c. OTHER ACCIDE			C. INSURANCE PLAN N	ME OR PROGRAM NA	ME
d INDIDANO	PLAN NAME OR I	POGRAMINA			ES NO	1000	d. IS THERE ANOTHER		NO
d. INSORANC	PLAN NAME OF I	-hogham name		100. CLAIM CODE	S (Designated by N	100)	YES N		items 9, 9a, and 9d.
12. PATIENT'S	READ BACK OF FORM BEFORE COMPLETING 12. PATIENT'S CR AUTHORIZED PERSON'S SIGNATURE Lauthorize the				ORM. I or other information	necessary	13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier		
to process below.	to process this claim. I also request payment of government benefits either below.				rty who accepts assig	nment	services described below.		
SIGNED _							SIGNED		
14. DATE OF MM DE	URRENT ILLNESS	8, INJURY, or PREG	NANCY (LMP) 15	UAL	MM DD	YY	16. DATES PATIENT UN	ABLE TO WORK IN CU	RRENT OCCUPATIO
17. NAME OF		IDER OR OTHER S					18. HOSPITALIZATION D		URRENT SERVICES
19 ADDITION		ATION (Designated		'b. NPI			FROM 20. OUTSIDE LAB?	TO	ARGES
							YES N		
				vice line below (24E)	ICD Ind.		22. RESUBMISSION CODE	ORIGINAL RE	F. NC BOX
_A <u> </u> H3531	3	B. L	C. G.		р. L		23. PRIOR AUTHORIZA	TON NUMBER	
	TE(S) OF SERVICE	J	К.	EDURES SERVICES	L L	F			
	TE(5) OF SERVICE	o PLACEO	F (Exp	iain Unusual Circumst	ances) ODIFIER	DIAGNOSIS POINTER	F	G. H. I. DAYS EPSDT ID. OR Farrier UNITS P	PROVIDER ID.
1. L 24. A. DA From MM DD	YY MM D				1 1		Box	15 Box	
MM DD			1						
MM DD N4736060	YY MM D		J278	I JZ	1 1	A	24F		2
MM DD	02001ML0.1	4B 1	J278			A A	24E	¹ 240	;
MM DD N4736060 2 3	Box 24						24E	1 240	<u></u>
N4736060	Box 24	for					24E	240	÷
AMM DD N4736060 2 3 ermanen SYFOV	Box 24	for tive					24E	1 240	·····
N4736066 2 3 2 3 2 3 3 4 2 3 3 4 2 3 3 4 2 3 3 4 2 3 3 4 2 3 3 4 2 3 4 5 7 5 7 5 7 5 7 5 7 7 5 7 7 7 7 7 7 7	Box 24 box 24 t J-code RE effect ober 1, 20	for tive 023	670				24E	1 240	<u>.</u>
2 3 Cermanen SYFOV Oct	Box 24 t J-code RE effect ober 1, 20 ed effect	for tive 023 tive BC	670)				24E	1 NPI	<u></u>
2 3 Permanen SYFOV Oct fier requir 2023, to a	Box 24 t J-code RE effect ober 1, 20 ed effect ttest that	tive 223 tive tive tno	670: D			A		1 NPI NPI NPI	
N4736066	Box 24 t J-code RE effect bber 1, 20 ed effec ttest that	tive D23 tive tive tive tive 24	670: D So. Patient's	28 RT		A	28. TOTAL CHARGE \$	240 1	
N4736066	Box 24 t J-code RE effect ober 1, 20 ed effect ttest that is discard or payme	tive D23 tive tive t no ded ent.	670: D So. Patient's	28 RT	YES	A GNMENT?	28. TOTAL CHARGE	240 1	
Permanen SYFOV Oct fier requir 2023, to a of drug wa d eligible	Box 24 t J-code RE effect bber 1, 20 ed effec ttest that	for tive D23 tive t no ded ent.	670: D So. Patient's	28 RT	YES	A GNMENT?	28. TOTAL CHARGE \$	240 1	

NOTE: Payers may vary in their specific billing and coding requirements. Please check with your patient's health plan to ensure you are providing accurate and complete information.

The JZ modifier is required starting July 1, 2023.⁴

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (CONTINUED)

Intraocular Inflammation

 In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

Increased Intraocular Pressure

 Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

Please see additional Important Safety Information throughout and full Prescribing Information.

Box 21:

Enter the appropriate ICD-10-CM code corresponding to the patient's diagnosis.

Box 23:

If available, report the Prior Authorization number here.

Shaded area below box 24A:

The payer may require the N4 qualifier immediately preceding the 11-digit NDC, the unit of measurement qualifier, and unit quantity.

Box 24B:

Enter the place of service for physician offices.

Box 24D:

Include all appropriate CPT codes, modifiers, and HCPCS codes. The JZ modifier is required starting July 1, 2023.⁴

Box 24E:

Specify the diagnosis letter from Box 21 relating to each CPT/HCPCS code listed in Box 24D.

Box 24G:

Enter the number of units for each CPT/HCPCS code. When using the permanent J-code, bill 15 units for each SYFOVRE injection. Check with each payer for their specific coding requirements.








Sample CMS-1450 (UB-04) Claim Form: Hospital Outpatient

Below is a sample CMS-1450 (UB-04) form for SYFOVRE claim submissions.

The sample claim form provided below is for illustrative purposes only. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, payment policies, and fee schedules.



NOTE: Payers may vary in their specific billing and coding requirements. Please check with your patient's health plan to ensure you are providing accurate and complete information.

The JZ modifier is required starting July 1, 2023.4

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

• Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see additional Important Safety Information throughout and full Prescribing Information.

Box 42:

Enter the appropriate revenue code corresponding to the HCPCS code and CPT code in Box 44.

Box 43:

Enter a detailed drug description, including the N4 qualifier immediately preceding the 11-digit NDC, the unit of measurement qualifier, and unit quantity.

Box 44:

Enter the appropriate HCPCS code for SYFOVRE as required by the payer, as well as the JZ modifier (required effective July 1, 2023). Also include the CPT code representing procedure performed, as well as the appropriate modifier.

Box 46:

Enter the number of HCPCS units administered. When using the permanent J-code, bill 15 units for each SYFOVRE injection. Check with each payer for their specific coding requirements.

Box 63:

If available, report the Treatment Authorization codes here.

Box 67:

Enter the appropriate ICD-10-CM code corresponding to the patient's diagnosis.





Tips for completing claim forms:

Ć

Ć

Ċ



Use the most appropriate ICD-10-CM and CPT codes associated with each patient's diagnosis and care

When using the permanent J-code J2781, bill 15 units for each SYFOVRE injection

Contact the payer prior to submitting the claim to confirm the payer's method for submission and if supporting documentation is required

Ensure the appropriate documentation that supports the information on the claim form is in the patient's medical record in case the payer requests it

Verify the claim for accuracy and file it as soon as possible, within each payer's filing time limits

Check your contract, or contact provider services at the payer to determine reimbursement

Questions? Please reach out to your Apellis Field Reimbursement Manager or the ApellisAssist® program

Apellis Assist Here for your patients

The ApellisAssist program can provide assistance on a range of topics, including insurance coverage requirements, claim submission policies and procedures, and billing and coding questions.

OR

To enroll your patients in ApellisAssist

Register for the portal and submit your request online at **ApellisAssistGA.com**

Download the Enrollment Form from **SyfovreECP.com** and fax the completed form to **888–405–6966**

Phone: 888-APELLIS (888-273-5547) 8 AM-8 PM ET, Monday-Friday

Website: SyfovreECP.com

Portal: ApellisAssistGA.com

Fax: 888-405-6966







INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

• SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

WARNINGS AND PRECAUTIONS

• Endophthalmitis and Retinal Detachments

o Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

 In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

Intraocular Inflammation

- In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
- Increased Intraocular Pressure
 - Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

• Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

Please see full <u>Prescribing Information</u> for more information.

References: 1. Lum F, Repka MX, Vicchrilli S. How to use the ICD-10 codes for age-related macular degeneration. *EyeNet Magazine*. 2017;9:61–62. 2. Coding for injectable drugs. American Academy of Ophthalmology. Accessed July 18, 2023. https://www.aao.org/practice-management/coding/ injectable-drugs 3. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations. Centers for Medicare & Medicaid Services. Accessed August 14, 2023. https://www.cms.gov/files/document/2023hcpcs-application-summary-quarter-2-2023-drugs-and-biologicals.pdf 4. Medicare program. Discarded drugs and biologicals – JW modifier and JZ modifier policy. Frequently asked questions. Centers for Medicare & Medicaid Services (CMS). Accessed July 21, 2023. https://www.cms.gov/ Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf 5. Syfovre. Prescribing information. Apellis Pharmaceuticals, Inc.; 2023. 6. Proposed rule on revising the national drug code format. US Food and Drug Administration. Updated December 27, 2022. Accessed July 18, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/proposed-rule-revising-national-drug-code-format 7. Revenue codes. Noridian Healthcare Solutions. Updated June 28, 2022. Accessed July 18, 2023. https://med.noridianmedicare.com/web/jea/ topics/claim-submission/revenue-codes



APELLIS®, APELLISASSIST®, SYFOVRE® and their respective logos are registered trademarks of Apellis Pharmaceuticals, Inc. Other trademarks referenced herein are the property of their respective owners. © 2023 Apellis Pharmaceuticals. All rights reserved. 9/23 US-PEGGA-2200294 v3.0